Main Article Content

Lalendra Yadav
Shaktibala Dutta
Jyotsna Sharma
Rajani Rai Sukla
Ila Pahwa


Antidiabetic Drugs, ADRs, B/R ration, Drug Safety


Introduction: In India, Diabetes Mellitus is probably becoming a pandemic. India's diabetes population is predicted to grow from approximately 69.2 million in 2015 to 123.5 million in 2040. It can be treated by various types of Antidiabetic Drugs that has not only beneficial effect; it also causes adverse drug reactions. 

Method:  This was a prospective and observational study conducted in Department of Pharmacology, Santosh Medical College in Collaboration with Department of Medicine, Muzaffarnagar Medical College (MMC), Muzaffarnagar, UP. A total of 109 Diabetic patients treated with Antidiabetic drugs presented in Medicine OPD of MMC Hospital were included and data were assessed for rational prescription as per WHO prescription indicators and also for drug safety concern.

Results: Maximum number of drug prescribed in this study was Biguanide derivative and its FDCs Sulphonylureas + Biguanide + Thiazolidinedione showed less number of ADRs (B/R, 0.13) is a safe drug either alone or with FDCs.

Conclusion: ADRs could be minimized with rational prescription and FDCs

Abstract 97 | pdf Downloads 47


1. American Diabetes Association. Standards of medical care in diabetes. Diabetes care 2013;36 Suppl 1:11-66.
2. WHO, Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva, Switzerland: World Health Organization; 1999. p. 31-3.
3. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6:CD007543.
4. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372 (23):2197-206.
5. Sen S, Chakraborty R, De B, Devanna N. Trends in diabetes epidemiology in Indian population in spite of regional disparities: A systemic review. Int J Diabetes Dev Ctries 2015; 35 (3):264-79.
6. International Diabetes Federation. IDF Diabetes; 7th ed. Brussels, Belgium: International Diabetes Federation; 2015. Available from: [Last accessed on 2016 Apr 10].
7. Sahu RK, Yadav R, Prasad P, Roy A and Chandrakar S: Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springer Plus 2014; 3: 695
8. Juarez DT, Sentell T, Tokumaru S, Goo R, Davis JW, Mau MM. Factors associated with poor glycemic control or wide glycemic variability among diabetes patients in Hawaii, 2006-2009. Prev Chronic Dis 2012; 9:120065.
9. Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, El-Kebbi IM, et al. Patient adherence improves glycemic control. Diabetes Educ 2005; 31(2):240-50.
10. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004; 27 (2):384-91.
11. Biswas P: Pharmacovigilance in Asia. Journal of pharmacology & pharmacotherapeutics 2013; 4(5): 7-13. Evaluation of Suspected Adverse Drug Reactions of Oral Anti-diabetic Drugs in a Tertiary Care Hospital for Type II Diabetes Mellitusiji Keezhipadathil 2023.
14. Ardoino, I.; Mandelli, S.; Baviera, M.; Rossio, R.; Nobili, A.; Mannucci, P.M.; Franchi, C.; on behalf of REPOSI Investigator. Antidiabetic Drug Prescription Pattern in Hospitalized Older Patients With Diabetes. Int. J. Environ. Res.Public Health 2023, 20, 2607.
12. Nitin S. HbA1c and factors other than diabetes mellitus affecting it. Singapore Med J 2010; 51 (8):616-22.
13. Delamater A. M. Improving patient adherence. Clin Diabetes 2006;24(2):71-7